A novel mode of action for COX‐2 inhibition: Targeting ATPase domain of HSP90 induces ubiquitin degradation of new client protein COX‐2-Reference-Cited by-同舟云学术

A novel mode of action for COX‐2 inhibition: Targeting ATPase domain of HSP90 induces ubiquitin degradation of new client protein COX‐2

Published:2022-01 Issue:1 Volume:12 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Zhang Man¹,Cui Jing¹,Shen Fukui¹,Ye Lili¹,Cheng Chuanjing¹,Li Yang¹,Zhang Qiuyang²,Niu Lin³,Hou Yuanyuan¹^ORCID,Bai Gang¹

Affiliation:

1. State Key Laboratory of Medicinal Chemical Biology College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research Nankai University Tianjin People's Republic of China

2. Thompson Rivers University Manna British Columbia Canada

3. Tianjin University of Traditional Chinese Medicine Tianjin People's Republic of China

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.705

Reference10 articles.

1. Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea;Marjoribanks J;Cochrane Database Syst Rev,2015

2. Inhibition of LPS-Induced iNOS, COX-2 and Inflammatory Mediator Expression by Paeonol through the MAPKs Inactivation in RAW 264.7 Cells

3. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders

4. Hsp90 as a capacitor for morphological evolution

5. In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active metabolites and potential mechanisms of Notopterygium incisum against obstructive sleep apnea Syndrome (OSAS): network analysis and experimental assessment;Frontiers in Pharmacology;2023-08-31

2. Magnolol alleviates pulmonary fibrosis inchronic obstructive pulmonary disease by targeting transient receptor potential vanilloid 4‐ankyrin repeat domain;Phytotherapy Research;2023-06-07